This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

60/100

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Long-term cohort studies

Topic: Amyloid, tau and blood-test diagnosis

Background The temporal relationship of cognitive deficit and functional impairment in Alzheimer's disease (AD) is not well characterized. Recent analyses suggest cognitive decline predicts subsequent functional decline throughout AD progression. Objective To better understand the relationship between cognitive and functional decline in mild AD using autoregressive cross-lagged (ARCL) panel analyses in several clinical trials.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Liu-Seifert, H., Siemers, E., Price, K., Han, B., Selzler, K. J., Henley, D., et al. (2015). Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease. Journal of Alzheimer's disease : JAD. https://doi.org/10.3233/jad-142508

Vancouver

Liu-Seifert H, Siemers E, Price K, Han B, Selzler KJ, Henley D, et al. Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease. Journal of Alzheimer's disease : JAD. 2015. doi:10.3233/jad-142508. PMID: 26402769.

BibTeX

@article{liuseifert2015-26402769,
  author  = {Liu-Seifert, H. and Siemers, E. and Price, K. and Han, B. and Selzler, K. J. and Henley, D. and Sundell, K. and Aisen, P. and others},
  title   = {{Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2015},
  doi     = {10.3233/jad-142508},
  pmid    = {26402769},
  url     = {https://doi.org/10.3233/jad-142508}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Recent analyses suggest cognitive decline predicts subsequent functional decline throughout AD progression.
Objective To better understand the relationship between cognitive and functional decline in mild AD using autoregressive cross-lagged (ARCL) panel analyses in several clinical trials.
Methods Data included placebo patients with mild AD pooled from two multicenter, double-blind, Phase 3 solanezumab (EXPEDITION/2) or semagacestat (IDENTITY/2) studies, and from AD patients participating in the Alzheimer's Disease Neuroimaging Initiative (ADNI).
Cognitive and functional outcomes were assessed using AD Assessment Scale-Cognitive subscale (ADAS-Cog), AD Cooperative Study-Activities of Daily Living instrumental subscale (ADCS-iADL), or Functional Activities Questionnaire (FAQ), respectively.

Why it matters

Using data from placebo patients in several clinical trials, this analysis found that cognitive decline predicts subsequent functional decline in mild Alzheimer's disease. This suggests that changes in thinking and memory come before changes in daily functioning as the disease progresses.

Study details

Study designclinical trial
Evidence strengthLow

How this study scored 60/100

Published in a peer-reviewed journal, and it is a large phase 3 trial. Scored zero for sample size and effect reported because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Journal of Alzheimer's disease : JAD)
Journal's citation record	2 / 4	Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29)
Study design	11 / 12	A large phase 3 trial (from PubMed type “Clinical Trial, Phase III”)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	1 / 5	2015 — within 20 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (pubmed indexes it as a clinical or observational study)
Randomised / blinded	1 / 2	Blinded or placebo-controlled (as stated in the record)
Times cited	4 / 7	Cited 78 times (OpenAlex, 2026-10-10)
Citations per year	2 / 5	6.0 citations a year over 13 year(s) since 2015
Impact for its field and year	3 / 6	Cited 6.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	2 / 6	Cited by 5 other studies in this library
Still being cited	2 / 4	Cited 17 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Richard C. Mohs: h-index 75 (OpenAlex, whole career)
Institution's track record	2 / 3	University of California San Diego: institution h-index 1,852 (OpenAlex)
Multi-centre collaboration	2 / 3	OpenAlex lists 6 institution(s) in 2 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 26402769)
Free to read	2 / 2	Free to read
Total	60 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 21.

Later studies that cite this one

5 studies in the alzhub library list this one in their references.

Related studies in Long-term cohort studies

Also tagged “examination”

840 studies in the library carry the topic tag “examination”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 840 tagged studies.

Similar studies

More on Long-term cohort studies

See all studies in Long-term cohort studies →